Skip to main content

3 Result(s)

within Bláthnaid McCoy Remove this filter Pharmacoeconomics and Health Outcomes Remove this filter Quality of Life Research Remove this filter

and

  1. No Access

    Article

    Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis

    Cannabinoid oils are being increasingly used to treat Dravet syndrome, yet the long-term costs and outcomes of this approach are unknown. Thus, we examined the cost effectiveness of cannabinoid oil as an adjun...

    Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter… in PharmacoEconomics (2020)

  2. No Access

    Article

    Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations

    Drug-resistant epilepsy affects about one-third of children with epilepsy and is associated with high costs to the healthcare system, yet the cost effectiveness of most treatments is unclear. Use of cannabis-b...

    Jesse Elliott, Sasha van Katwyk, Bláthnaid McCoy, Tammy Clifford… in PharmacoEconomics (2019)

  3. No Access

    Article

    Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis

    Dravet syndrome is a catastrophic form of pediatric treatment-resistant epilepsy with few effective treatment options. Stiripentol is approved for use in Canada for treatment of Dravet syndrome, but the associ...

    Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, George A. Wells… in PharmacoEconomics (2018)